Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib plus GDP in refractory/relapsed non-GCB DLBCL
NCT02542111Phase 2Unknown
- Sponsor
- Ruijin Hospital
- Start
- May 2015
- Primary completion
- May 2018
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in diffuse large B-cell lymphoma (DLBCL), sponsored by Ruijin Hospital. Primary endpoint: Response rate at 2 years. Status: unknown.
02
Drugs
bortezomib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02542111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02542111.